Abbott Laboratories has raised the U.S. price of a key AIDS drug by 400%, a move that could roil the market for HIV treatments and has already reignited the debate over drug pricing policies.
Abbott Laboratories has raised the U.S. price of a key AIDS drug by 400%, a move that could roil the market for HIV treatments and has already reignited the debate over drug pricing policies.